References

1. De Oliveira MS, Jaffe ES, Catovsky D. Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases. J Clin Pathol 1989;42;962-972.

2. Bartlett NL, Longo DL. T-small lymphocyte disorders. Semin Hematol 1999;36:164-170.

3. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours (WHO): Pathology and Genetics; Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001, p. 190.

4. D'Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64:275-281.

5. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25:6-10.

6. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia 1996;10,:877-895.

7. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:22-47.

8. Cabezudo E, Carrara P, Morilla R, Matutes E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999;84:413-418.

9. Zomas AP, Matutes E, Morilla R, et al. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b) Leukemia 1996;10:1966-1970.

10. Alfarano A, Indraccolo S, Circosta P, et al. An alternatively spliced form of CD79b gene may account for altered B- cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999;93:2327-2335.

11. Catovsky D, Cherchi M, Brookss D, Bradely J, Zola H. Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981;58:406-408.

12. Huh YO, Pugh WC, Kantarjian HM, et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994;101:283-289.

13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989;42:567-584.

14. Criel A, Verhoef G, Vlietinck R, et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol 1997;97:383-391.

15. Finn WG, Thangavelu M, Yelavarthi KK, et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol 1996;105:458-467.

16. Criel A, Michaux L, Wolf-Peeters C. The concept of typical and atypical chronic lymphocytic leukaemia. Leuk Lymph 1999;33:33-45.

17. Cartron G, Linassier C, Bremond JL, et al. CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases. Leuk Lymph 1998;31:209-216.

18. Shapiro JL, Miller ML, Pohlman B, Mascha E, Fishleder AJ. CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients. Am J Clin Pathol 1999;111: 477-487.

19. Frater JL, McCarron KF, Hammel JP, et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol 2001;116:655-664.

20. D'Arena G, Dell'Olio M, Musto P, et al. Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. Leuk Lymph 2001;42:649-654.

21. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92:382-388.

22. Oscier DG, Matutes E, Copplestone A, et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 1997;98:934-939.

23. Matutes E, Carrara P, Coignet L, et al. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias. Leukemia 1999;13:1721-1726.

24. Cuneo A, Bigoni R, Negrini M, et al. Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCL1 translocation. Cancer Res 1997;57:1144-1150.

25. Huang JC, Finn WG, Goolsby CL, Variakojis D, Peterson LC. CD5- small B-cell leukemias are rarely classifiable as chronic lymphocytic leukemia. Am J Clin Pathol 1999;111:123-130.

26. Carey JL. Immunophenotyping in diagnosis and prognosis of mature lymphoid leukemias and lymphomas. In: Keren D, McCoy JP, Carey JL, eds. Flow Cytometry in Clinical Diagnosis. ASCP Press, Chicago, 2001, pp. 227-378.

27. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989;42:567-584.

28. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol 1996;105:451-457.

29. Wormsley SB, Baird SM, Gadol N, Rai KR, Sobol RE. Characteristics of CD11c+CD5+ chronic B-cell leukemias and the identification of novel peripheral blood B-cell subsets with chronic lymphoid leukemia immunophenotypes. Blood 1990;76:123-130.

30. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645.

31. Fermand JP, Brouet JC. Heavy-chain diseases. Hematol Oncol Clin N Am 1999;13:1281-1294.

32. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994;83:1558-1562.

33. Ferry JA, Yang WI, Zukerberg LR, et al. CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 1996;105:31-37.

34. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-821.

35. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-1447.

36. Lin CW, O'Brien S, Faber J, et al. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol 1999;112:828-835.

37. Kroft SH, Dawson DB, Mckenna RW. Large cell lymphoma transformation of chronic lymphocytic leukemia/ small lymphocytic lymphoma. A flow cytometric analysis of seven cases. Am J Clin Pathol 2001;115:385-395.

38. Cornfield DB, Mitchell Nelson DM, Rimsza LM, Moller-Patti D, Braylan RC. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells. Am J Hematol 2001;67:223-226.

39. Tiesinga JJ, Wu CD, Inghirami G. CD5+ follicle center lymphoma. Immunophenotyping detects a unique subset of "floral" follicular lymphoma. Am J Clin Pathol 2000;114:912-921.

40. Raza A, Alvi S, Broady-Robinson L, et al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous. Exp Hematol 1997;25:530-535.

41. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997;14:629-640.

42. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.

43. van Dierendonck JH, Wijsman JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki- 67 staining. Am J Pathol 1991;138:1165-1172.

44. Trere D. Quantitative analysis of AgNOR proteins: a reliable marker of the rapidity of cell duplication and a significant prognostic parameter in tumour pathology. Adv Clin Path 1998;2:261-270.

45. Kallander CF, Simonsson B, Gronowitz JS, Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur J Haematol 1987;38:331-337.

46. Holm M, Thomsen M, Hoyer M, Hokland P. Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. Cytometry 1998;32:28-36.

47. Glasova M, Konikova E, Kusenda J, Babusikova O. Evaluation of different fixation-permeabilization methods for simultaneous detection of surface, cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines. Neoplasma 1995;42:337-346.

48. Bierman HR. The leukemias—proliferative or accumulative? Blood 1967;30:238-250.

49. Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood 1967;29(suppl):566-584.

50. Themi H, Trepel F, Schick P, Kaboth W, Begemann H. Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. Blood 1973;42:623-636.

51. Stryckmans PA, Debusscher L, Collard E. Cell kinetics in chronic lymphocytic leukaemia (CLL). Clin Haematol 1977;6:159-167.

52. Theml H, Love R, Begemann H. Factors in the pathomechanism of chronic lymphocytic leukemia. Annu Rev Med 1977;28:131-141.

53. Matsuda S, Uchida T, Kariyone S. Kinetic studies on lymphocytes labelled with indium 111-oxine in patients with chronic lymphocytic leukaemia. Scand J Haematol 1985;35:210-218.

54. Petti MC, Testa MG, Deb G, Amadori S. Cytokinetic studies in chronic lymphocytic leukemia. Relationship to other variables at diagnosis and survival. Biomedicine 1980;33:188-190.

55. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980;55:282-293.

56. de Melo N, Matutes E, Cordone I, Morilla R, Catovksy D. Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders. J Clin Pathol 1992;45:660-663.

57. Stephenson CF, Desai ZR, Bridges JM. The proliferative activity of B-chronic lymphocytic leukaemia lymphocytes prior to and after stimulation with TPA and PHA. Leuk Res 1991;15:1005-1012.

58. Lin CW, Manshouri T, Jilani I, et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 2002;26:551-559.

59. Diamond LW, Bearman RM, Berry PK, et al. Prolymphocytic leukemia: flow microfluorometric, immunologic, and cytogenetic observations. Am J Hematol 1980;9:319-330.

60. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002;16:327-334.

61. Garcia-Marco JA, Price CM, Ellis J, et al. Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 1996; 10:1705-1711.

62. Juliusson G, Gahrton G. Clinical implications of CLL cell proliferation in vitro. Nouv Rev Fr Hematol 1988; 30:399-401.

63. Moayeri H, Sokal JE. In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemia. Am J Med 1979;66:773-778.

64. Simonsson B, Nilsson K. 3H-thymidine uptake in chronic lymphocytic leukaemia cells. Scand J Haematol 1980; 24:169-173.

65. Kimby E, Mellstedt H, Nilsson B, et al. Blood lymphocyte characteristics as predictors of prognosis in chronic lymphocytic leukemia of B-cell type. Hematol Oncol 1988;6:47-55.

66. Orfao A, Ciudad J, Gonzalez M, et al. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia 1992;6:47-51.

67. Astsaturov IA, Samoilova RS, Iakhnina EI, Pivnik AV, Vorobiov AI. The relevance of cytological studies and Ki-67 reactivity to the clinical course of chronic lymphocytic leukemia. Leuk Lymph 1997;26:337-342.

68. Vinolas N, Reverter JC, Urbano-Ispizua A, Montserrat E, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance. Blood Cells 1987;12:457-470.

69. del Giglio A, O'Brien S, Ford R, et al. Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood 1992;79:2717-2720.

70. Cordone I, Matutes E, Catovsky D. Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity. Leukemia 1992;6:902-906.

71. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998;91:4694-4700.

72. Dormer P, Theml H, Lau B. Chronic lymphocytic leukemia: a proliferative or accumulative disorder? Leuk Res 1983;7:1-10.

73. Schwartz BR, Pinkus G, Bacus S, Toder M, Weinberg DS. Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining. Am J Pathol 1989;134:327-336.

74. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984;2:365-371.

75. Weiss LM, Strickler JG, Medeiros LJ, Gerdes J, Stein H, Warnke RA. Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Hum Pathol 1987;18:1155-1159.

76. Witzig TE, Gonchoroff NJ, Greipp PR, et al. Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure. Am J Clin Pathol 1989;91:298-301.

77. Sebo TJ, Roche PC, Witzig TE, Kurtin PJ. Proliferative activity in non-Hodgkin's lymphomas. A comparison of the bromodeoxyuridine labeling index with PCNA immunostaining and quantitative image analysis. Am J Clin Pathol 1993;99:668-672.

78. Lindh J, Jonsson H, Lenner P, Roos G. 'Aggressive' low grade lymphocytic lymphomas can be identified by flow cytometric S-phase determinations. Hematol Oncol 1992;10:171-179.

79. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.

80. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993;11:1985-1989.

81. Nikicicz EP, Norback DH. Spectrum of argyrophilic nucleolar organizer region (AgNOR) staining patterns in chronic and transformed B-cell leukemias. Arch Pathol Lab Med 1992;116:265-268.

82. Cobo F, Martinez A, Pinyol M, et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2002;16:1028-1034.

83. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal he-matopoiesis and hematological malignancies. Blood 1999;93:3587-3600.

84. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;387:773-776.

85. Gottardi D, Alfarano A, De Leo AM, et al. In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996;94:612-618.

86. Klein A, Miera O, Bauer O, Golfier S, Schriever F. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000;14: 40-46.

87. Raghoebier S, van Krieken JH, Kluin-Nelemans JC, et al. Oncogene rearrangements in chronic B-cell leukemia. Blood 1991;77:1560-1564.

88. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11-18.

89. Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphobytic leukemia cells. Blood 1992;79:2981-2989.

90. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-1828.

91. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996;156: 2624-2630.

92. Krajewski S, Gascoyne RD, Zapata JM, et al. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood 1997;89:3817-3825.

93. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymph 1998;28:355-361.

94. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71: 343-350.

95. Mainou-Fowler T, Prentice AG. Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Leuk Lymph 1996;21:369-377.

96. Aguilar-Santelises M, Magnusson KP, Wiman KG, Mellstedt H, Jondal M. Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. Int J Cancer 1994;58:474-479.

97. Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol. Cell Biol 1997;75:127-135.

98. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-218.

99. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176: 1319-1326.

100. Molica S, Vitelli G, Levato D, Levato L, Dattilo A, Gandolfo GM. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia. Haematologica 1999;84:208-211.

101. Plate JM, Long BW, Kelkar SB. Role of beta2 integrins in the prevention of apoptosis induction in chronic lymphocytic leukemia B cells. Leukemia 2000;14:34-39.

102. Cordingley FT, Bianchi A, Hoffbrand AV, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988;1:969-971.

103. Gamberale R, Geffner JR, Trevani A, et al. Immune complexes inhibit apoptosis of chronic lymphocytic leukaemia B cells. Br J Haematol 1999;107:870-876.

104. Schattner EJ. Cd40 ligand in cll pathogenesis and therapy. Leuk Lymph 2000;37:461-472.

105. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-3057.

106. Laytragoon-Lewin N, Duhony E, Bai XF, Mellstedt H. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells. Eur J Haematol 1998;61:266-271.

107. Kneitz C, Goller M, Wilhelm M, et al. Inhibition of T cell/B cell interaction by B-CLL cells. Leukemia 1999; 13:98-104.

108. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 2000;79:157-173.

109. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-274.

110. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.

111. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91: 2387-2396.

112. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.

113. Ricciardi MR, Petrucci MT, Gregorj C, et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol 2001;113:391-399.

114. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459.

115. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998;91:3379-3389.

116. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.

117. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998;91:4342-4349.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment